ProCE Banner Activity

CME

Expert Recommendations for the Diagnosis and Treatment of Axial Spondyloarthritis

In this interactive multimedia presentation, gain expert insights on current guidelines and best practice for your patients with axial spondyloarthritis.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: July 30, 2020

Expiration: July 29, 2021

No longer available for credit.

Share

Faculty

Atul Deodhar

Atul Deodhar, MD

Professor of Medicine
Medical Director, Rheumatology Clinics
Oregon Health & Science University
Portland, Oregon

Provided by

Provided by Purdue University College of Pharmacy
ProCE Banner

Supporters

This activity is supported by educational funding provided by

AbbVie Inc.

Novartis Pharmaceuticals Corporation

Target Audience

This educational activity is intended for rheumatologists, primary care physicians, and other clinicians managing patients with axSpA.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the evaluation of patients who may have axSpA including clinical presentation, laboratory studies, and appropriate imaging studies to improve early diagnosis
  • Review the ASAS classification criteria for axSpA
  • Discuss extra-articular manifestations and QoL concerns seen in patients with axSpA
  • Apply the guideline recommendations for the management of axSpA
  • Describe agents in late-stage development for axSpA

Program Director Disclosure

Program Director

Atul Deodhar, MD

Professor of Medicine
Medical Director, Rheumatology Clinics
Oregon Health & Science University
Portland, Oregon

Atul Deodhar, MD, has disclosed that he has received consulting fees from and has served on advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Galapagos, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, and UCB and has received funds for research support from AbbVie, GlaxoSmithKline, Lilly, Novartis, Pfizer, and UCB.

Staff Disclosure

Staff

Pranali Pathare, PhD

Editorial Contributor

Pranali Pathare, PhD, has no relevant conflicts of interest to report.

Anne Roc, PhD

Director, Scientific Services

Anne Roc, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.

Instructions for Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and Clinical Care Options, LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 30, 2020, through July 29, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to increase the knowledge and competence in diagnosing and managing axSpA (including differentiating nr-axSpA and AS and applying current guidelines based on new and emerging therapies) among rheumatology and primary care clinicians.